We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gaucher's disease oral therapy gets nod from FDA.
- Authors
Sinha, Gunjan
- Abstract
The article reports on the approval of the Cerdelga, the first oral therapy to treat type I Gaucher's disease, by the U.S. Food and Drug Administration (FDA) in August 2014. The drug was made by Cambridge, Massachusetts-based Genzyme Corp., a Sanofi-Aventis SA company. Mark Clark, a biotech analyst at Deutsche Bank AG in London, England, states analysts do not expect a market sweep, despite the drug's convenience and comparable efficacy.
- Subjects
GAUCHER'S disease treatment; DRUG efficacy; GENZYME Corp.; SANOFI-Aventis SA; CLARK, Mark; DEUTSCHE Bank AG
- Publication
Nature Biotechnology, 2014, Vol 32, Issue 10, p970
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt1014-970